Product information and disease description
Product description
81 evidence topics · 22 sources
Azetukalner (XEN1101)
Focal onset seizures
- Manufacturer
- Xenon Pharmaceuticals
- Regulatory submission
- NDA submitted September 2026
- Launch
- Not announced
- Last updated